April 2005
Worldwide Biotech;Apr2005, Vol. 17 Issue 4, p1
Trade Publication
Focuses on the deal between drug delivery and development company OctoPlus and protein therapeutics firm Biolex Inc. to co-develop a controlled release formulation of recombinant human alfa interferon called Locteron. Characteristics of the drug; Terms of the deal; Background information on the operations of Biolex.


Related Articles

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on results from a Phase IIa study by Biolex Therapeutics Inc. of Pittsboro, North Carolina about Locteron, controlled-release interferon alpha 2b, reduced flu-like symptoms in patients treated with pegylated (PEG) interferon. Hepatitis C virus (HCV) patients received...

  • Biolex Steams Ahead in Making Plant-Based Therapeutics a Reality. Jarvis, Lisa // Chemical Market Reporter;11/24/2003, Vol. 264 Issue 18, p12 

    Reports on the drug development program of Biolex Inc. Pittsboro, North Carolina. Cost improvement in mammalian cell systems; Preparation from human clinical trials; Sources of venture capital funding.

  • Alliances Update.  // PharmaWatch: Biotechnology;Apr2005, Vol. 4 Issue 4, p15 

    The article presents updates on business alliances in the biotechnology industry. A joint venture has been formed by Teva Pharmaceutical Industries Ltd. and Gamida-Cell Ltd. to develop and market their stem cell therapeutic, StemEx for the treatment of lymphoma and leukemia. Biolex Inc. and...

  • Advances in Single-Shot Vaccine Development. Kremer, Bas; Roukema, Rianne; de Leede, Leo // BioPharm International;Jan2009 Supplement, p28 

    The article describes the manufacture of a prototype single-shot vaccine that combines a prime and booster dose in one injection based on the example of hepatitis B vaccination. Accordingly, the vaccine uses OctoPlus NV's OctoVAX microsphere technology, which has been proven to be well-tolerated...

  • OctoPlus Shares Rise on Locteron Deal with Biolex. Sheridan, Cormac // BioWorld International;10/8/2008, Vol. 13 Issue 41, p1 

    The article reports on a 13.6 percent increase in OctoPlus NV's share price. The share price increased after the company announced that it could earn up to $149 million in payments from out-licensing its controlled-release formulation of alpha interferon, Locteron, to its co-development partner...

  • Biolex Raises $60M, Buys Rest of Locteron Rights from OctoPlus. Morrison, Trista // BioWorld Today;10/7/2008, Vol. 19 Issue 195, p1 

    The article reports on the $60 million in a Series D financing raised by Biolex Therapeutics Inc. to complete its ongoing Phase II program with Locteron, a controlled-release version of interferon alpha for hepatitis C. It was noted that Biolex has obtained full rights to the compound from...

  • Biolex Raises $60M, Buys Rest of Locteron Rights.  // Bioworld Week;10/13/2008, Vol. 16 Issue 41, p3 

    The article reports on the initiative of Biolex Therapeutics Inc. to raise $60 million in a Series D financing to complete its ongoing Phase II program with Locteron. It is stated that Biolex bought full rights to locteron from partner Octopus NV. The locteron which is a controlled-release...

  • Pond Pills.  // Technology Review;May2001, Vol. 104 Issue 4, p23 

    Focuses on Biolex's efforts to develop the use of genetically engineered duckweeds to make complex therapeutic proteins. Advantage of duckweeds over genetically engineered bacteria and yeast for churning out protein pharmaceuticals; Therapeutic proteins that can be grown from duckweeds.

  • OCTOPLUS/LUMC BEGIN TRIALS FOR MIDDLE EAR INFECTION DRUG.  // Worldwide Biotech;Mar2004, Vol. 16 Issue 3, p5 

    Focuses on the partnership between Octoplus and Leiden University Medical Centre on conducting patient trials for a drug against chronic middle ear infection.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics